Feb 8 | News
SAN DIEGO (AP) — Diagnostics company Illumina Inc. again rejected a $5.7 billion offer from Roche AG on Tuesday, saying the Swiss drugmaker's bid was "grossly inadequate."
|
Jan 31 | News
U.S. health care giant McKesson Corp. is buying a big part of drug store operator Katz Group Canada Inc. for $920 million Canadian (US$918 million)
|
Jan 30 | News
Valeant Pharmaceuticals International, Inc. today announced that it has withdrawn its offer to acquire ISTA Pharmaceuticals Inc. for $7.50 per share in cash.
|
Jan 26 | News
Amgen and Micromet, Inc. today announced that the companies have entered into a definitive merger agreement under which Amgen will acquire Micromet ...
|
Jan 25 | News
Roche has offered to acquire all outstanding shares of Illumina for $44.50 per share in cash, or approximately $5.7 billion, to strengthen its position in the diagnostics field.
|
Jan 24 | News
Watson Pharmaceuticals said Tuesday it has bought Strides Arcolab's generics unit Ascent Pharmahealth for 375 million Australian dollars ($393 million) in cash.
|
Jan 19 | News
Jazz Pharmaceuticals has closed its all-stock acquisition of privately held Azur Pharma Ltd., a deal that creates a specialty drug company incorporated in Ireland.
|
Jan 18 | News
Takeda Pharmaceutical Company Limited announced today strategic measures to better align its global workforce and consolidate site operations in order to integrate legacy Nycomed operations, strengthen its presence in more than 70 countries, adapt to changing market conditions and maintain a focus on growth.
|
Jan 17 | News
ISTA Pharmaceuticals announced today that it has received a revised non-binding proposal from Valeant Pharmaceuticals to acquire ISTA and will consider the updated proposal as part of its ongoing review of strategic options.
|
Jan 13 | News
NEW YORK & PRINCETON, N.J.-Bristol-Myers Squibb Company is commencing today, through its wholly owned subsidiary Inta Acquisition Corporation, a cash tender offer to purchase all outstanding shares of common stock of Inhibitex, Inc. Bristol-Myers Squibb announced on Saturday, January 7, 2012 its intent to acquire Inhibitex.
|